Analytical Solution for Electrical Problem Forced by a Finite-Length Needle Electrode: Implications in Electrostimulation

[EN] Needle electrodes, widely used in clinical procedures, are responsible for creating an electric field in the treated biological tissue. This is achieved by setting a constant voltage along the length of their metallic section. In accordance with Laplace's equation, the electric field is spatially non-uniform around the electrode surface. Mathematical modelling can provide useful information on the spatial distribution of electrical fields. Indeed, exact solutions for the electrical problem are indispensable for validating numerical codes. All the analytical models developed to date to solve the needle electrode electrical problem have been one-dimensional models, which assumed an electrode of infinite length. We here propose the first analytical solution based on a two-dimensional model that considers the real length of the electrode in which the Laplace equation is solved through the method of separation of variables, dealing with the nonhomogeneous source term and boundary conditions by Green's functions. On assuming a needle electrode of given length, the problem combines boundary conditions on the electrode boundary (of the first and second kind). Since this rules out using the Sturm-Liouville Theorem, the problem is decomposed into two different problems and the principle of superposition is used. The solution obtained can reproduce a reasonable electric field around the electrode, especially the edge effect characterized by an extremely high gradient around the electrode tip.This work was supported by the Universidad Autonoma de San Luis Potosi (Mexico), which granted R. Romero-Mendez who is on a sabbatical leave to do research in the field of biomedical engineering. This work was supported by the Spanish Ministerio de Ciencia, Innovacion y Universidades under "Programa Estatal de I+D+i Orientada a los Retos de la Sociedad" (grant number: RTI2018-094357-B-C21).Romero-Méndez, R.; Pérez-Gutiérrez, FG.; Oviedo-Tolentino, F.; Berjano, E. (2019). Analytical Solution for Electrical Problem Forced by a Finite-Length Needle Electrode: Implications in Electrostimulation. Mathematical Problems in Engineering. 1-10. https://doi.org/10.1155/2019/2404818S110Mulier, S., Miao, Y., Mulier, P., Dupas, B., Pereira, P., de Baere, T., … Ni, Y. (2005). Electrodes and multiple electrode systems for radiofrequency ablation: a proposal for updated terminology. European Radiology, 15(4), 798-808. doi:10.1007/s00330-004-2584-xMerrill, D. R., Bikson, M., & Jefferys, J. G. R. (2005). Electrical stimulation of excitable tissue: design of efficacious and safe protocols. Journal of Neuroscience Methods, 141(2), 171-198. doi:10.1016/j.jneumeth.2004.10.020Cogan, S. F. (2008). Neural Stimulation and Recording Electrodes. Annual Review of Biomedical Engineering, 10(1), 275-309. doi:10.1146/annurev.bioeng.10.061807.160518Kwon, H., Rutkove, S. B., & Sanchez, B. (2017). Recording characteristics of electrical impedance myography needle electrodes. Physiological Measurement, 38(9), 1748-1765. doi:10.1088/1361-6579/aa80acBurdío, F., Berjano, E. J., Navarro, A., Burdío, J. M., Güemes, A., Grande, L., … de Gregorio, M. A. (2007). RF tumor ablation with internally cooled electrodes and saline infusion: what is the optimal location of the saline infusion? BioMedical Engineering OnLine, 6(1), 30. doi:10.1186/1475-925x-6-30Zhang, B., Moser, M. A. J., Zhang, E. M., Luo, Y., Liu, C., & Zhang, W. (2016). A review of radiofrequency ablation: Large target tissue necrosis and mathematical modelling. Physica Medica, 32(8), 961-971. doi:10.1016/j.ejmp.2016.07.092Samoudi, A. M., Kampusch, S., Tanghe, E., Széles, J. C., Martens, L., Kaniusas, E., & Joseph, W. (2017). Numerical modeling of percutaneous auricular vagus nerve stimulation: a realistic 3D model to evaluate sensitivity of neural activation to electrode position. Medical & Biological Engineering & Computing, 55(10), 1763-1772. doi:10.1007/s11517-017-1629-7Samoudi, A. M., Vermeeren, G., Tanghe, E., Van Holen, R., Martens, L., & Josephs, W. (2016). Numerically simulated exposure of children and adults to pulsed gradient fields in MRI. Journal of Magnetic Resonance Imaging, 44(5), 1360-1367. doi:10.1002/jmri.25257Trujillo, M., Bon, J., José Rivera, M., Burdío, F., & Berjano, E. (2016). Computer modelling of an impedance-controlled pulsing protocol for RF tumour ablation with a cooled electrode. International Journal of Hyperthermia, 32(8), 931-939. doi:10.1080/02656736.2016.1190868Ewertowska, E., Mercadal, B., Muñoz, V., Ivorra, A., Trujillo, M., & Berjano, E. (2017). Effect of applied voltage, duration and repetition frequency of RF pulses for pain relief on temperature spikes and electrical field: a computer modelling study. International Journal of Hyperthermia, 34(1), 112-121. doi:10.1080/02656736.2017.1323122Zhang, B., Moser, M. A. J., Zhang, E. M., Luo, Y., & Zhang, W. (2016). A new approach to feedback control of radiofrequency ablation systems for large coagulation zones. International Journal of Hyperthermia, 33(4), 367-377. doi:10.1080/02656736.2016.1263365Haemmerich, D., Chachati, L., Wright, A. S., Mahvi, D. M., Lee, F. T., & Webster, J. G. (2003). Hepatic radiofrequency ablation with internally cooled probes: effect of coolant temperature on lesion size. IEEE Transactions on Biomedical Engineering, 50(4), 493-500. doi:10.1109/tbme.2003.809488López Molina, J. A., Rivera, M. J., & Berjano, E. (2017). Analytical transient-time solution for temperature in non perfused tissue during radiofrequency ablation. Applied Mathematical Modelling, 42, 618-635. doi:10.1016/j.apm.2016.10.044Romero-Méndez, R., & Berjano, E. (2017). An Analytical Solution for Radiofrequency Ablation with a Cooled Cylindrical Electrode. Mathematical Problems in Engineering, 2017, 1-12. doi:10.1155/2017/9021616Verhey, J., Nathan, N., Rienhoff, O., Kikinis, R., Rakebrandt, F., & D’Ambra, M. (2006). BioMedical Engineering OnLine, 5(1), 17. doi:10.1186/1475-925x-5-1

Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: Results from the CREDENCE trial and meta-analysis

BACKGROUND AND PURPOSE: Chronic kidney disease with reduced estimated glomerular filtration rate or elevated albuminuria increases risk for ischemic and hemorrhagic stroke. This study assessed the effects of sodium glucose cotransporter 2 inhibitors (SGLT2i) on stroke and atrial fibrillation/flutter (AF/AFL) from CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation) and a meta-Analysis of large cardiovascular outcome trials (CVOTs) of SGLT2i in type 2 diabetes mellitus. METHODS: CREDENCE randomized 4401 participants with type 2 diabetes mellitus and chronic kidney disease to canagliflozin or placebo. Post hoc, we estimated effects on fatal or nonfatal stroke, stroke subtypes, and intermediate markers of stroke risk including AF/AFL. Stroke and AF/AFL data from 3 other completed large CVOTs and CREDENCE were pooled using random-effects meta-Analysis. RESULTS: In CREDENCE, 142 participants experienced a stroke during follow-up (10.9/1000 patient-years with canagliflozin, 14.2/1000 patient-years with placebo; hazard ratio [HR], 0.77 [95% CI, 0.55-1.08]). Effects by stroke subtypes were: ischemic (HR, 0.88 [95% CI, 0.61-1.28]; n=111), hemorrhagic (HR, 0.50 [95% CI, 0.19-1.32]; n=18), and undetermined (HR, 0.54 [95% CI, 0.20-1.46]; n=17). There was no clear effect on AF/AFL (HR, 0.76 [95% CI, 0.53-1.10]; n=115). The overall effects in the 4 CVOTs combined were: Total stroke (HRpooled, 0.96 [95% CI, 0.82-1.12]), ischemic stroke (HRpooled, 1.01 [95% CI, 0.89-1.14]), hemorrhagic stroke (HRpooled, 0.50 [95% CI, 0.30-0.83]), undetermined stroke (HRpooled, 0.86 [95% CI, 0.49-1.51]), and AF/AFL (HRpooled, 0.81 [95% CI, 0.71-0.93]). There was evidence that SGLT2i effects on total stroke varied by baseline estimated glomerular filtration rate (P=0.01), with protection in the lowest estimated glomerular filtration rate (45 mL/min/1.73 m2]) subgroup (HRpooled, 0.50 [95% CI, 0.31-0.79]). CONCLUSIONS: Although we found no clear effect of SGLT2i on total stroke in CREDENCE or across trials combined, there was some evidence of benefit in preventing hemorrhagic stroke and AF/AFL, as well as total stroke for those with lowest estimated glomerular filtration rate. Future research should focus on confirming these data and exploring potential mechanisms

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to 300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m 2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to &lt;90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], &gt;300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of &lt;15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P&lt;0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P&lt;0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years

Beneficios fiscales de las PyMES en México, integradas a una empresa integradora

Seminario: Alternativas para cumplir estrictamente con las obligaciones fiscale